Efficacy of protease inhibitor from marine Streptomyces sp. VITBVK2 against Leishmania donovani - An in vitro study.
In the present study the leishmanicidal effect of potential protease inhibitor producing marine actinobacterial isolate has been investigated against Leishmania donovani, the causative agent of visceral leishmaniasis. Among 89 marine actinobacteria isolated from a salt pan in Kanyakumari, only one isolate (BVK2) showed 97% of protease inhibition activity against trypsin. Moderate to high protease inhibitor activity was shown by isolate BVK2 on proteinase (30%) and chymotrypsin (85%). In optimization study for protease inhibitor production glucose as carbon source and casein as nitrogen source showed the best activity. In the in-vitro Fluorescence-activated cell sorting (FACS) assay, 100 μg/ml of BVK2 extract was active against amastigotes in infected J774A.1 macrophages and showed 87% of parasitic inhibition. The isolate BVK2 showed significant anti-parasitic activity with an IC50of 27.1 μg/ml after double doses were administered. The potential isolate was identified by molecular 16S rRNA gene sequencing as Streptomyces sp. VITBVK2. The results obtained suggest that the marine actinobacterial extract which have novel metabolites can be considered as a potential source for the development of drugs.
Molecular and Microbiology Research Laboratory, Department of Biomedical Sciences, School of Bio Sciences and Technology, VIT University, Vellore 632 014, Tamil Nadu, India.
Veena
V
Sreedharan
Molecular and Microbiology Research Laboratory, Department of Biomedical Sciences, School of Bio Sciences and Technology, VIT University, Vellore 632 014, Tamil Nadu, India. Electronic address: kokatibhaskar@yahoo.co.in.
K V
KV
Bhaskara Rao
D000981:Antiprotozoal Agents / Q000302:isolation & purification / Q000494:pharmacology*; D002364:Caseins / Q000378:metabolism; D002918:Chymotrypsin / Q000037:antagonists & inhibitors; D005434:Flow Cytometry; D019015:Geologic Sediments / Q000382:microbiology; D005947:Glucose / Q000378:metabolism; D020128:Inhibitory Concentration 50; D007893:Leishmania donovani / Q000187:drug effects* / Q000201:enzymology; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000469:parasitology; D008264:Macrophages / Q000469:parasitology; D008855:Microscopy, Electron, Scanning; D010447:Peptide Hydrolases / Q000187:drug effects / Q000378:metabolism; D010802:Phylogeny; D011480:Protease Inhibitors / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology*; D013302:Streptomyces / Q000737:chemistry* / Q000145:classification / Q000302:isolation & purification / Q000648:ultrastructure; D014357:Trypsin / Q000187:drug effects
D000981:Antiprotozoal Agents; D002364:Caseins; D011480:Protease Inhibitors; D010447:Peptide Hydrolases; D002918:Chymotrypsin; D014357:Trypsin; D005947:Glucose
Leishmania donovani; Leishmanicidal activity; Marine actinobacteria; Protease inhibitor; Streptomyces sp.